Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Inflammation is likely a key contributor to the pathogenesis of Parkinson's disease (PD), a progressively debilitating neurodegenerative disease that is accompanied by a pathological accumulation of the α-synuclein protein in a staged manner through the brain. What leads to the accumulation of α-synuclein in PD and how this relates to inflammatory pathways, however, is not entirely clear. Toll-like receptor (TLR) signaling is a major pathway mediating inflammation and, in particular, TLR2 is increasingly being implicated in PD. We have, therefore, examined the expression of TLR2 in postmortem brain tissue from PD patients and matched controls. We confirm that TLR2 is increased in PD brain, and find that levels of TLR2 correlate with the accumulation of pathological α-synuclein. TLR2 was expressed on neurons as well as microglia; however, the neuronal rather than glial expression of TLR2 was significantly increased in PD brain in accordance with disease staging, and TLR2 was strongly localized to α-synuclein positive Lewy bodies. In cell culture, activation of neuronal TLR2 induced an inflammatory response, including the secretion of inflammatory cytokines and microglial-activating chemokines, as well as the production of reactive oxygen species. Moreover, activation of neuronal TLR2 increased levels of endogenous α-synuclein protein, which was in turn associated with increased levels of the autophagy/lysosomal pathway marker p62. Finally, promoting autophagy with rapamycin or pharmacological inhibition of the TLR2 signaling pathway prevented the TLR2-mediated increase in α-synuclein in neuronal cell cultures. These results implicate neuronal TLR2 expression in human PD pathogenesis. In particular, the increased expression of TLR2 on neurons may provide new insight into disease pathogenesis and/or options for therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of neuronal TLR2 in the brains of patients with Parkinson's disease results in increased proinflammatory cytokine (TNF) levels and recruitment of microglia to amplify neuroinflammation as well as increased expression of asynuclein.158”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [158]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TLR2 also plays a role in neurons in response to α-synuclein in addition to microglia19,57,58.”
From Microglia clear neuron-released α-synuclein via selective autophagy and prevent neurodegeneration (2020) · cites this paper as [57]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It has been suggested that TLR2 expression is upregulated in PD postmortem human brains.291,292”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [292]
The cited source says what the claim attributes to it.
In the citing paper
“TLR2 also plays a role in neurons in response to α-synuclein in addition to microglia19,57,58.”
From Microglia clear neuron-released α-synuclein via selective autophagy and prevent neurodegeneration (2020) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · cited 1×
“Gene expression was quantified using the comparative Ct method [24] with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the housekeeping gene.”
MethodStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Pathologically, PD is defined by the selective degeneration of dopamine-producing neurons in the substantia nigra pars compacta with concomitant accumulation of α-synuclein-rich proteinaceous neuronal inclusions, termed Lewy bodies, which propagate in a predicative or staged fashion through multiple brain regions [5,…”
BackgroundSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity
Kawai, T., & Akira, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.006 · Cited by 3,658 · cited 1×
“TLRs mediate the recognition of exogenous conserved structures known as pathogen-associated molecular patterns (PAMPs) [18], and endogenous damage-associated molecular patterns (DAMPs) [33].”
BackgroundMcGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990 · cited 1×
“1 3 cytokines are increased in the brain, CSF and serum of PD patients [7, 17, 31] and activated microglia are prevalent in the most pathologically effected areas of the brains of patients with PD [26].”
Backgroundα-Synuclein is phosphorylated in synucleinopathy lesions
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., & Iwatsubo, T. (2002) · Nature Cell Biology · doi:10.1038/ncb748 · Cited by 2,132
Cutting Edge: Role of Toll-Like Receptor 1 in Mediating Immune Response to Microbial Lipoproteins
Takeuchi, O., Sato, S., Horiuchi, T., Hoshino, K., Takeda, K., Dong, Z., Modlin, R. L., & Akira, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.10 · Cited by 1,329 · cited 1×
“4b), which specifically activates TLR2/ TLR1 dimers [40].”
BackgroundZhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265 · cited 2×
“Recent reports have suggested that α-synuclein is a DAMP, capable of modulating inflammatory cytokine production in microglia [1, 3, 21, 39, 47].”
Background
Cited by
Items 201–280 of 280
Imaging in Neurodegeneration: Movement Disorders
Sossi, V., Cheng, J.-C. K., & Klyuzhin, I. S. (2018) · IEEE Transactions on Radiation and Plasma Medical Sciences · doi:10.1109/trpms.2018.2871760 · Cited by 6
“And finally, microglial activation is only one of the possible inflammatory pathways; recent studies are showing that toll-like receptor 2 is increased in neurons in PD brain and that such increase could contribute to α-synuclein pathology [45].”
BackgroundWang, X., Yang, G., Lai, Y., Li, Y., & Liu, X. (2024) · Journal of Molecular Neuroscience · doi:10.1007/s12031-024-02272-w · Cited by 5
“In addition, TLR2 is expressed in microglia and neurons and can participate in inflammatory responses through multiple pathways, such as the activation of microglia and the secretion of inflammatory factors such as IL-6 and TNF (Flynn et al. 2019; Da Sobrinho et al. 2021; Dzamko et al. 2017).”
Han, D., Zhang, C., Huang, R., & Gao, Y. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103220 · Cited by 4
Innate Immune Mechanisms in the Central Nervous System
Shastri, A., Yasmin, H., & Kishore, U. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-85340-1_15 · Cited by 4
Kim, R.-E., Mabunga, D. F. N., Boo, K.-J., Kim, D. H., Han, S., Shin, C. Y., & Kwon, K. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910594 · Cited by 9
“Among the TLRs, TLR2 and TLR4 are well known to be associated with disorders related to the brain, such as AD, PD, and stroke [33–36].”
BackgroundBu, F., Guan, R., Wang, W., Liu, Z., Yin, S., Zhao, Y., & Chai, J. (2022) · Medicine · doi:10.1097/md.0000000000032100 · Cited by 4
“…Compared to healthy brain samples with very low TLR2 expression, autopsy analysis of brain samples from PD patients showed increased TLR2 expression in neurons and microglia in different brain regions, [69] which is consistent with the results of blood samples tested from PD and healthy patients.”
ResultProgress of Immunotherapies in Parkinson's Disease
Peng, Y., Kang, X., Yao, S., Zhang, X., Sugimoto, K., Liu, J., Du, M., Lin, L.-Y., Jiang, D., Chen, Q., et al. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70964 · Cited by 3
Iba, M., Lee, Y., Kwon, S., Horan-Portelance, L., Chang, K., Kim, M., Landeck, N., Rissman, R. A., Lee, S. J., You, S., et al. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01564-4 · Cited by 4
Bisht, K. S., Kumari, M., & Maiti, T. K. (2025) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2025.110701 · Cited by 3
Bae, E.-J., Ham, S., Jeong, Y. W., Yang, W. S., Shin, J., Lee, W.-J., Ahn, W. J., Yoon, Y.-S., Lee, H.-J., Lee, S. H., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68870-x · Cited by 3
“Among these, TLR2 is upregulatedinPDandDLBpatients 8,9 ,anditsroleinsynucleinopathies has been independently validated by several researchers 9,41,42 TLR2 is involved in both neuron-to-neuron α Syn propagation and α Syn oligomer-induced microglial activation.”
Natala, S. R., Habas, A., Stocking, E. M., Orry, A. J. W., Abagyan, R. A., Makale, M., & Wrasidlo, W. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130259 · Cited by 3
USP18 is a key regulator of immune function in mouse midbrain microglia
Lü, L., Jifu, C., Pei, B., Gao, X., Xu, Z., Yin, X., Xia, J., & Wang, J. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123692 · Cited by 4
Klein, S. (2020) · USURJ University of Saskatchewan Undergraduate Research Journal · doi:10.32396/usurj.v6i2.425 · Cited by 4
Kaur, G., Behl, T., Sehgal, A., Singh, S., Sharma, N., Kumar, A., Arora, S., & BUNGAU, S. G. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01811-z · Cited by 3
RetractedYao, K., Wang, L., & Zhang, L. (2023) · International Journal of Clinical Practice · doi:10.1155/2023/9514851 · Cited by 4
An Overview of Alpha Synuclein Protein and Its Role in Parkinson’s disease
Kaya, Z. B., & Atilla, P. (2021) · Acta Medica · doi:10.32552/2021.actamedica.510 · Cited by 4
“Similarly, when neuronal TLR2 is activated, there is an increase of inflammatory cytokine levels which leads an increase of oxidative stress and also accumulation of endogenous α-syn protein [90].”
BackgroundInfluentialLiu, Z., Lemus, J., Smirnova, I. V., & Liu, W. (2023) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2023.00049 · Cited by 3
Neuronal vulnerability in Parkinson’s disease: insights from murine α-synuclein pathology models
Asadpoordezaki, Z., & Prehn, J. H. M. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.04.007 · Cited by 2
Contribution of neuroinflammation, resolution, and neuroprotection in neuropsychiatric diseases
Farooqui, A. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-88460-0.00002-3 · Cited by 3
Contribution of neuroinflammation, resolution, and neuroprotection in neurodegenerative diseases
Farooqui, A. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-88460-0.00010-2 · Cited by 5
Нейроиммунные механизмы нейродегенеративных заболеваний: роль цитокинов и толл-подобных рецепторов
(2018) · Сибирский вестник психиатрии и наркологии · doi:10.26617/1810-3111-2018-2(99)-99-104 · Cited by 2
Neuroinflammation and Immune Dysfunction in the Mechanisms of Development of Parkinson’s Disease
Idova, G. V., Лазаревна, А. Е., & Zhanaeva, S. Y. (2023) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-023-01549-8 · Cited by 2
“PD patients show increases in the expression of TLR2 and ionized calcium-binding adapter molecule 1 (IBA1), a microglial marker (IBA1 + cells) over levels in controls [Dzamko et al., 2017].”
InfluentialKoyanagi, Y., Kassai, M., & Yoneyama, H. (2024) · Microorganisms · doi:10.3390/microorganisms12010106 · Cited by 2
“This hypothesis is supported by the increased expression of TLR2 observed in the brain and peripheral tissues of patients with PD [27–29] and the suppression of pathologic changes in inflammatory responses and α -synuclein aggregate accumulation in the brains of TLR2-knockout (TLR2-KO) in the SNCA…”
BackgroundThe rapeutic impact of alkaloids in neurological diseases: A promising key molecule
Kaur, S., Kaur, G., Rana, R., Kumar, B., Melkani, I., Kumar, S., Pandey, N. K., Singh, S., Baghel, D. S., Joshi, K., et al. (2024) · E3S Web of Conferences · doi:10.1051/e3sconf/202455601004 · Cited by 4
Immune Sensors, Regulators, and Effectors of Brain Health
Acıoğlu, Ç., & Elkabes, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_3 · Cited by 2
Alpha-synuclein and neuroinflammation in Parkinson's disease
Varanita, T., & Bubacco, L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815950-7.00027-8 · Cited by 2
STUDI IN SILICO PENGHAMBATAN AKTIVASI TLR2 EKSTRAK ETANOL DAUN SEMANGGI (Marsilea crenata Presl.)
Ma’arif, B., Fihuda, D. A. P., Muslikh, F. A., Syarifuddin, S., Fauziyah, B., Sari, D. P., & Agil, M. (2022) · Jurnal Tumbuhan Obat Indonesia · doi:10.22435/jtoi.v15i1.5792 · Cited by 7
Research Progress of Toll-Like Receptors in Neurosystem-Related Diseases
梁, 欣. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1492513 · Cited by 1
Idova, G. V., Zhanaeva, S. Y., Лазаревна, А. Е., Dzemidovich, S. S., Gevorgyan, M. M., Kulikova, K. I., & Aftanas, L. I. (2025) · Biochemistry (Moscow) · doi:10.1134/s0006297925600334 · Cited by 1
“At the same time, it is known that precisely transduction of the TLR2 signals is the main pathway mediating inflammation [14], which indicates an important role of TLR2 in the development of inflammatory process in PD.”
InfluentialJin, T., Shi, R.-Z., Shi, J.-W., Liu, F., & Liang, Y. (2025) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2025.2544148 · Cited by 1
Parkinson's disease: A chronic systemic inflammatory disorder
Khan, H., & Benskey, M. J. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-21992-4.00006-3 · Cited by 1
Diverse Effects of Various Toll-Like Receptor 2 Ligands on Neuronal Activity and Cell Death
Sato, F., & Hachimura, S. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01632-3 · Cited by 1
“Previous studies have reported that a neuronal cell line upregulate cytokine gene expression via TLR2 (Dzamko et al. 2017) and that both neuronal cells and microglia express TLR2 in mouse brain tissue (Kim et al. 2013).”
Singh, S., Capacio, A., Braun, C. A., Carroll‐Portillo, A., Ryman, S. G., & Lin, H. C. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1672793 · Cited by 1
“Activation of TLR-2 has been shown to increase the expression of α-syn protein and its accumulation in aggregates (Dzamko et al., 2017; Kim C. et al., 2015).”
Kumari, P., & Singh, L. (2026) · NeuroMolecular Medicine · doi:10.1007/s12017-026-08908-x · Cited by 1
“Moreover, mature IL-1β is released through these N-GSDMD pores, amplifying the inflammatory response (Yu et al., 2021 ).”
InfluentialAPOE4-Expressing Astrocytes Exhibit Parkinson’s Disease–Related Pathology
Nechushtai, L., Anna, P., Roni, H., Daniel, M. M., Dan, F., & Pinkas‐Kramarski, R. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05996-5 · Cited by 1
“These results are in agreement with previous studies showing that TLR2 mRNA and protein levels are significantly upregulated in the brains of PD patients and in animal models of synucleinopathy [31, 32].”
Tian, C., Sun, J., Wang, J., Wang, Y., Wan, P., Sun, G., Mu, Y., Geng, M., Xu, B., & Zhang, Y. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102718 · Cited by 1
“TLR2 expression is significantly upregulated across multiple brain regions in PD patients and correlates with α -synuclein accumulation [14].”
Palmas, M. F., Aminzadeh, K., Runfola, M., Parekh, P., Porcedda, C., Tweedie, D., Casula, L., Cardia, M. C., Marongiu, J., Etzi, M., et al. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-026-01549-8 · Cited by 1
Cluster analysis of immunological serum markers in patients with Parkinson’s disease
Klyushnik, T. P., Simonov, A. N., Androsova, L. V., Ponomareva, N. V., & Illarioshkin, S. N. (2019) · Annals of Clinical and Experimental Neurology · doi:10.25692/acen.2019.3.1 · Cited by 1
NEUROINFLAMMATION AND IMMUNE DYSFUNCTION IN THE PATHOGENESIS OF PARKINSON’S DISEASE
Idova, G. V., Лазаревна, А. Е., & Zhanaeva, S. Y. (2023) · Журнал высшей нервной деятельности им И П Павлова · doi:10.31857/s0044467723040056 · Cited by 2
Parkinson’s Disease and Other Synucleinopathies
Cookson, M. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00006-7
Characterizing the Role of α-Synuclein in Innate Defenses
Rousso, C. (2020) · uO Research (University of Ottawa) · doi:10.20381/ruor-24250
Insulin resistance and Parkinson’s disease
Farooqui, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819603-8.00007-9
Molecular mechanisms of neurodegeneration in neurodegenerative diseases
Farooqui, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821711-5.00004-8
Zhang, K., Wu, J., Jiang, W., Wang, Y., Rong, Z., Sun, L. Z., & Cheng, Y. X. (2020) · Research Square · doi:10.21203/rs.3.rs-126752/v1
Mikroglial Toll-benzeri Reseptörlerin Alzheimer ve Parkinson Hastalıklarındaki Rolü
Samur, D. N., & Özbey, G. (2021) · Akdeniz Medical Journal · doi:10.53394/akd.981907 · Cited by 1
Role of Inflammation in Lewy Body Dementia
Surendranathan, A., & O'Brien, J. T. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108539623.011
بررسی توزیع تنش در فک پایین با تغییر ناحیه جوش (Bitting) در پروتز کامل به روش اجزای محدود
رستمیان, ج., شریفی, ا., پژند, م. ر., & سرافرازی, س. (2001)
Alimentos infantiles para el periodo lácteo: parte I
Berruezo, G. F. R. (2009) · ANS. Alimentación, nutrición y salud
(2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811351-6.00026-7
xie, X., Su, S., Huang, Y., Cui, Q., & Zang, W. (2023) · SSRN Electronic Journal · doi:10.21203/rs.3.rs-2906856/v1 · Cited by 1
(2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.09996-8
Inflammatory Roads to Parkinson’s Disease
Anisman, H., Hayley, S. P., & Kusnecov, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.00015-6
Mechanisms of Autophagy and Its Dysregulation in Neurodegenerative Diseases
Singhmura, S., Tallapragada, S. D., Ganguly, A., Chakraborty, J., Basu, A., & Dey, Y. N. (2025) · Springer eBooks · doi:10.1007/978-981-95-3945-1_2
The role of Toll-like receptors in Parkinson's disease
Kennedy, C. (2023) · Apollo (University of Cambridge) · doi:10.17863/cam.106123
Riboldi, G. M., Vialle, R. A., Navarro, E., Udine, E., de Paiva Lopes, K., Humphrey, J., Allan, A., Parks, M., Henderson, B., Astudillo, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20508692
Riboldi, G. M., Vialle, R. A., Navarro, E., Udine, E., de Paiva Lopes, K., Humphrey, J., Allan, A., Parks, M., Henderson, B., Astudillo, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20508698
Riboldi, G. M., Vialle, R. A., Navarro, E., Udine, E., de Paiva Lopes, K., Humphrey, J., Allan, A., Parks, M., Henderson, B., Astudillo, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20508689
Amo‐Aparicio, J., Daly, J., Højen, J. F., & Dinarello, C. A. (2024) · Figshare · doi:10.6084/m9.figshare.26599028
Quan, P., Li, X., Si, Y., Sun, L., Ding, F. F., Fan, Y., Liu, H., Wei, C., Li, R., Zhao, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25530327
Riboldi, G. M., Vialle, R. A., Navarro, E., Udine, E., de Paiva Lopes, K., Humphrey, J., Allan, A., Parks, M., Henderson, B., Astudillo, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20508695
Riboldi, G. M., Vialle, R. A., Navarro, E., Udine, E., de Paiva Lopes, K., Humphrey, J., Allan, A., Parks, M., Henderson, B., Astudillo, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20508683
Additional file 2 of Neuroinflammation and protein pathology in Parkinson’s disease dementia
Kouli, A., Camacho, M., Allinson, K. S. J., & Williams‐Gray, C. H. (2020) · Figshare · doi:10.6084/m9.figshare.13331727
Iba, M., McDevitt, R. A., Kim, C., Roy, R., Sarantopoulou, D., Tommer, E., Siegars, B., Sallin, M. A., Kwon, S., Sen, J. M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20967836
Riboldi, G. M., Vialle, R. A., Navarro, E., Udine, E., de Paiva Lopes, K., Humphrey, J., Allan, A., Parks, M., Henderson, B., Astudillo, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20508701
Quan, P., Li, X., Si, Y., Sun, L., Ding, F. F., Fan, Y., Liu, H., Wei, C., Li, R., Zhao, X. L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26701096
Additional file 1 of Neuroinflammation and protein pathology in Parkinson’s disease dementia
Kouli, A., Camacho, M., Allinson, K. S. J., & Williams‐Gray, C. H. (2020) · Figshare · doi:10.6084/m9.figshare.13331724
Additional file 3 of Neuroinflammation and protein pathology in Parkinson’s disease dementia
Kouli, A., Camacho, M., Allinson, K. S. J., & Williams‐Gray, C. H. (2020) · Figshare · doi:10.6084/m9.figshare.13331730
Riboldi, G. M., Vialle, R. A., Navarro, E., Udine, E., de Paiva Lopes, K., Humphrey, J., Allan, A., Parks, M., Henderson, B., Astudillo, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20508686
Additional file 4 of Neuroinflammation and protein pathology in Parkinson’s disease dementia
Kouli, A., Camacho, M., Allinson, K. S. J., & Williams‐Gray, C. H. (2020) · Figshare · doi:10.6084/m9.figshare.13331733
Riboldi, G. M., Vialle, R. A., Navarro, E., Udine, E., de Paiva Lopes, K., Humphrey, J., Allan, A., Parks, M., Henderson, B., Astudillo, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20508680
Cheng, Y., Tong, Q., Yuan, Y., Song, X., Jiang, W., Wang, Y., Li, W., Li, Y., & Zhang, K. (2024) · Figshare · doi:10.6084/m9.figshare.26568502
Quan, P., Li, X., Si, Y., Sun, L., Ding, F. F., Fan, Y., Liu, H., Wei, C., Li, R., Zhao, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25530423
Thornton, J. M., & Stevenson, J. L. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877251412923 · Cited by 1
“…with a history of scabies demonstrated a 1.46-fold increased risk of developing PD. 60 In fl ammation, chitin, and the blood-brain barrier 63 TLR-2 is a leading force in the pathogenesis of PD. 64,65 TLRs contribute to initiating a microglial in fl ammatory response to advance AD pathogenesis.”
InfluentialYildirim-Balatan, C. (2021) · theses.fr (ABES) · doi:10.70675/3372ff2ez69a6z4970z881bze4dfe0a15571
Sabouri, E., Shahmoradi, T., Keshvari, N. Z., khodaee, P., Saleki, K., & Rezaei, N. (2026) · Reviews in the Neurosciences · doi:10.1515/revneuro-2026-0064
Rusin, A., Cocchetto, A. M., & Mothersill, C. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146535
Aktürk, S. S. (2023) · Bilkent University Institutional Repository (Bilkent University)
Le, C., Dong, X., Bian, Y., Liu, Y., Gu, X., Zhang, X., Yang, J., & Li, L. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118531
Celik, U., Elibol, B., Beker, M., Cakmak, R. K., Ercin, N., Johnson, B. S., Karacan, İ., & Yıldız, G. B. (2026) · Biomedicines · doi:10.3390/biomedicines14112584
Bae, H. E., Sung, J. S., Nam, J., Kang, M.-J., Yoo, H. S., Jose, J., Lee, M., & Pyun, J. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.155243
Metadata
- Authors
- Dzamko, N., Gysbers, A., Perera, G., Bahar, A., Shankar, A., Gao, J., Fu, Y., & Halliday, G. M.
- Affiliations
- UNSW Sydney (AU)
- Neuroscience Research Australia (AU)
- Corresponding author
- Dzamko, Nicolas
- Halliday, Glenda M.
- Venue
- Acta Neuropathologica
- Published
- 2016-11-25
- Volume
- 133
- Issue
- 2
- Pages
- 303-319
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC5250664
- OpenAlex
- W2554874133
- Semantic Scholar
- 6d5ed92f5026eb13731b365c8793acdf5588d2a7
- Cited by
- 273
- References
- 49
- Citations by year
- 2026: 11 · 2025: 24 · 2024: 34 · 2023: 35 · 2022: 42 · 2021: 40 · 2020: 26 · 2019: 23 · 2018: 24 · 2017: 12
- FWCI
- 14.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Health and Medical Research Council
- Parkinson's NSW
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, TLR2, alpha-synuclein, neuroinflammation, Lewy bodies, microglia, autophagy, p62, reactive oxygen species, inflammatory cytokines, chemokines, disease staging, rapamycin, TLR2 signaling
- MeSH terms
- Aged, Aged, 80 and over, Brain, Female, Humans, Inflammation, Male, Middle Aged, Parkinson Disease, Toll-Like Receptor 2, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.